Krystal Biotech, Inc. Operating Lease Cost
Krystal Biotech, Inc. (KRYS) reported Operating Lease Cost of $366.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-03
- Krystal Biotech, Inc. operating lease, cost for the quarter ending 2026-06-30 was $366.00K, a 5.67% decline year-over-year.
- Krystal Biotech, Inc. operating lease, cost for the quarter ending 2026-03-31 was $411.00K, a 3.52% decline year-over-year.
- Krystal Biotech, Inc. operating lease, cost for the quarter ending 2025-12-31 was $412.00K, a 32.90% increase year-over-year.
- Krystal Biotech, Inc. operating lease, cost for the quarter ending 2025-09-30 was $368.00K, a 41.54% increase year-over-year.
- Krystal Biotech, Inc. operating lease, cost for fiscal 2025 was $1.59M, a 31.19% increase from fiscal 2024.
- Krystal Biotech, Inc. operating lease, cost for fiscal 2024 was $1.22M, a 23.87% decline from fiscal 2023.
- Krystal Biotech, Inc. operating lease, cost for fiscal 2023 was $1.60M, a 4.18% increase from fiscal 2022.
- Krystal Biotech, Inc. operating lease, cost for fiscal 2022 was $1.53M, a 20.16% increase from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $366.00K 10-Q · filed 2026-08-03 | $777.00K 10-Q · filed 2026-08-03 | $1.19M derived: sum of 3 quarters · filed 2026-08-03 | $1.56M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $411.00K 10-Q · filed 2026-05-04 | $823.00K derived: sum of 2 quarters · filed 2026-05-04 | $1.19M derived: sum of 3 quarters · filed 2026-05-04 | $1.58M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $412.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $780.00K derived: sum of 2 quarters · filed 2026-02-17 | $1.17M derived: sum of 3 quarters · filed 2026-08-03 | $1.59M 10-K · filed 2026-02-17 |
| 2025-09-30 | $368.00K 10-Q · filed 2025-11-03 | $756.00K derived: sum of 2 quarters · filed 2026-08-03 | $1.18M 10-Q · filed 2025-11-03 | $1.49M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $388.00K 10-Q · filed 2026-08-03 | $814.00K 10-Q · filed 2026-08-03 | $1.12M derived: sum of 3 quarters · filed 2026-08-03 | $1.38M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $426.00K 10-Q · filed 2026-05-04 | $736.00K derived: sum of 2 quarters · filed 2026-05-04 | $996.00K derived: sum of 3 quarters · filed 2026-05-04 | $1.34M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $310.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $570.00K derived: sum of 2 quarters · filed 2026-02-17 | $916.00K derived: sum of 3 quarters · filed 2026-02-17 | $1.22M 10-K · filed 2026-02-17 |
| 2024-09-30 | $260.00K 10-Q · filed 2025-11-03 | $606.00K derived: sum of 2 quarters · filed 2025-11-03 | $905.00K 10-Q · filed 2025-11-03 | $1.22M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-06-30 | $346.00K 10-Q · filed 2025-08-04 | $645.00K 10-Q · filed 2025-08-04 | $959.00K derived: sum of 3 quarters · filed 2026-02-17 | $1.34M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-03-31 | $299.00K 10-Q · filed 2025-05-06 | $613.00K derived: sum of 2 quarters · filed 2026-02-17 | $992.00K derived: sum of 3 quarters · filed 2026-02-17 | $1.43M derived: sum of 4 quarters · filed 2026-02-17 |
| 2023-12-31 | $314.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $693.00K derived: sum of 2 quarters · filed 2026-02-17 | $1.13M derived: sum of 3 quarters · filed 2026-02-17 | $1.60M 10-K · filed 2026-02-17 |
| 2023-09-30 | $379.00K 10-Q · filed 2024-11-04 | $819.00K derived: sum of 2 quarters · filed 2024-11-04 | $1.28M 10-Q · filed 2024-11-04 | $1.61M derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-06-30 | $440.00K 10-Q · filed 2024-08-05 | $902.00K 10-Q · filed 2024-08-05 | $1.24M derived: sum of 3 quarters · filed 2025-02-19 | $1.63M derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-03-31 | $463.00K 10-Q · filed 2024-05-06 | $795.00K derived: sum of 2 quarters · filed 2025-02-19 | $1.19M derived: sum of 3 quarters · filed 2025-02-19 | $1.58M derived: sum of 4 quarters · filed 2025-02-19 |
| 2022-12-31 | $332.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $731.00K derived: sum of 2 quarters · filed 2025-02-19 | $1.12M derived: sum of 3 quarters · filed 2025-02-19 | $1.53M 10-K · filed 2025-02-19 |
| 2022-09-30 | $399.00K 10-Q · filed 2023-11-06 | $790.00K derived: sum of 2 quarters · filed 2023-11-06 | $1.20M 10-Q · filed 2023-11-06 | $1.64M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | $391.00K 10-Q · filed 2023-08-07 | $800.00K 10-Q · filed 2023-08-07 | $1.24M derived: sum of 3 quarters · filed 2024-02-26 | $1.58M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | $409.00K 10-Q · filed 2023-05-08 | $848.00K derived: sum of 2 quarters · filed 2024-02-26 | $1.19M derived: sum of 3 quarters · filed 2024-02-26 | $1.47M derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | $439.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $778.00K derived: sum of 2 quarters · filed 2024-02-26 | $1.06M derived: sum of 3 quarters · filed 2024-02-26 | $1.27M 10-K · filed 2024-02-26 |
| 2021-09-30 | $339.00K 10-Q · filed 2022-11-07 | $617.00K derived: sum of 2 quarters · filed 2022-11-07 | $836.00K 10-Q · filed 2022-11-07 | $1.14M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $278.00K 10-Q · filed 2022-08-08 | $497.00K 10-Q · filed 2022-08-08 | $805.00K derived: sum of 3 quarters · filed 2023-02-27 | $953.00K derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $218.00K 10-Q · filed 2022-05-09 | $527.00K derived: sum of 2 quarters · filed 2023-02-27 | $675.00K derived: sum of 3 quarters · filed 2023-02-27 | $820.00K derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $309.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $457.00K derived: sum of 2 quarters · filed 2023-02-27 | $602.00K derived: sum of 3 quarters · filed 2023-02-27 | $767.00K 10-K · filed 2023-02-27 |
| 2020-09-30 | $148.00K 10-Q · filed 2021-11-08 | $293.00K derived: sum of 2 quarters · filed 2021-11-08 | $458.00K 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $145.00K 10-Q · filed 2021-08-09 | $310.00K 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | $164.00K 10-Q · filed 2021-05-10 | |||
| 2019-09-30 | $167.00K 10-Q · filed 2020-11-09 | $332.00K derived: sum of 2 quarters · filed 2020-11-09 | $449.00K 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $165.00K 10-Q · filed 2020-08-07 | $282.00K 10-Q · filed 2020-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |